A database of FDA approved therapeutic peptides and proteins
ID1038 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandEligard | CompanyAtrix Labs/QLT In | Physical AppearanceSuspension | Route of AdministartionSubcutaneous Injection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1039 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandEnantone | CompanyTakeda | Physical AppearanceSolution | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1040 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLeuplin | CompanyTakeda | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1041 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLeuProMaxx | CompanyBaxter/Teva | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1042 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLeupromer | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1043 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLupron | CompanyAbbott/TAP Pharmaceuticals | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1044 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLutrate | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1045 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandMemryte | CompanyCuraxis | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1046 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandProstap 3 | CompanyTakeda UK Limited | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1047 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandProstap SR | CompanyTakeda UK Limited | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1048 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandViadur | CompanyBayer AG | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1215 | ThPPIDTh1029 | NameMenotropins | Peptide SequenceAlpha-Chain(LH):APD< Full view | Length222 | Functional ClassificationIb | DiseaseHormonal disorders | BrandMenopur | CompanyN.A. | Physical AppearanceSterile, lyophilized powder which is reconstitution with sterile 0.9% Sodium Chloride Injection. | Route of AdministartionSubcutaneous Injection | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor,Lutropin-choriogonadotropic hormone receptor |
ID1216 | ThPPIDTh1029 | NameMenotropins | Peptide SequenceAlpha-Chain(LH):APD< Full view | Length222 | Functional ClassificationIb | DiseaseHormonal disorders | BrandRepronex | CompanyN.A. | Physical AppearanceSterile, lyophilized form | Route of AdministartionSubcutaneous or Intramuscular Injection. | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor,Lutropin-choriogonadotropic hormone receptor |
ID1269 | ThPPIDTh1039 | NameLutropin alfa | Peptide SequenceAlpha Chain: APDVQDC Full view | Length213 | Functional ClassificationIb | DiseaseHormonal | BrandLuveris | CompanySerono | Physical AppearanceWhite lyophilised pellet withg clear colourless solvent to make solution | Route of AdministartionSubcutaneous (SC) administration | CategoryFertility Agents | TargetLutropin-choriogonadotropic hormone receptor |
ID1372 | ThPPIDTh1055 | NameFollitropin beta | Peptide SequenceA Chain: APDVQDCPECT Full view | Length204 | Functional ClassificationIb | DiseaseHormonal disorders | BrandFollistim AQ | CompanyMerck | Physical AppearanceSterile aqueous solution | Route of AdministartionSubcutaneous or Intramuscular administration | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor |
ID1439 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandBRAVELLE | CompanyFerring Pharmaceuticals Inc. | Physical AppearanceSterile, lyophilized powder used after reconstitution with sterile 0.9% Sodium Chloride Injection | Route of AdministartionIntramuscular and Subcutaneous administration | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |
ID1440 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandMetrodin | CompanyN.A. | Physical AppearanceSterile, lypholized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Route of AdministartionIntramuscular injection. | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |
ID1441 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandFertinex | CompanyN.A. | Physical AppearanceSterile, lyophilized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Route of AdministartionSubcutaneous injection. | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |
ID1447 | ThPPIDTh1080 | NameChoriogonadotropin Alfa | Peptide SequenceAlpha chain: APDVQDC Full view | Length237 | Functional ClassificationIb | DiseaseHormonal | BrandChoriogonadotropin alfa | CompanyEmd serono inc, Ferring pharmaceuticals inc, App pharmaceuticals llc, Bel mar laboratories inc, Bris | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryFertility Agents and Gonadotropins | TargetIntegrin alpha-L, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |